ロード中...
Analysis of hematological parameters as prognostic markers for toxicity and survival of (223)Radium treatment
(223)Radium ((223)Ra) has emerged as treatment prolonging survival in patients with metastatic castration-resistant prostate cancer (CRPC). As (223)Ra can cause hematotoxicity (HT), pre-existing hematopoiesis might influence the efficacy of (223)Ra and the rate of hematotoxicity, but as to our knowl...
保存先:
| 出版年: | Oncotarget |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Impact Journals LLC
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5882327/ https://ncbi.nlm.nih.gov/pubmed/29662636 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24610 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|